Bifogade filer
Dicot Pharma AB Year End Report 2025 ENG
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Uppsala, Sweden, February 18, 2026. Dicot Pharma AB publishes its Year-End Report for 2025. The report is available as an attached document and on www.dicotpharma.com. The company will present the report in a webcast on Wednesday February 18 at 12.00 CET, a broadcast that may also be viewed afterwards.
Fourth quarter, October-December 2025
- Net sales amounted to SEK 0.0 (0.0) million
- Earnings after financial items amounted to SEK -16.8 (-20.8) million
- Earnings per share amounted to SEK -0.01 (-0.01)
Full year 2025
- Net sales amounted to SEK 0.0 (0.0) million
- Earnings after financial items amounted to SEK -80.2 (-57.7) million
- Earnings per share amounted to SEK -0.04 (-0.05)
”The positive results from the phase 2a study of LIB-01 reported in October demonstrated a unique long-acting effect on erectile function lasting up to eight weeks after treatment. This represents a significant advancement over current treatments, moving beyond temporary symptom relief to potentially restore sexual vitality, self-confidence, intimacy, and quality of life”, comments Elin Trampe, CEO.
Significant events during the quarter
- Positive topline results from the phase 2a study show improvement in erectile function at weeks 4 and 8, after only 3 days of oral treatment with LIB-01 at the start of the study. LIB-01 was well tolerated at all dose levels. The results mean that Dicot Pharma will proceed with the development according to plan with initiation of a phase 2b clinical.
- A new patent application was filed based on the long-term effect of eight weeks documented in the phase 2a clinical trial, which distinguishes LIB-01 significantly from current treatments for erectile dysfunction.
- New findings on the mechanism of action showed that LIB-01 affects the melanocortin system, well known for regulating functions such as sexual function and energy metabolism. The findings support LIB-01's potential to improve erectile function even in non-responders of current treatments and the possibility of use in other indication areas.
- Agreement was signed with international CRO for preparatory activities for phase 2b, to be initiated during second half of 2026 and conducted in the US and Europe.
Significant events after the quarter
- Dicot Pharma has been invited to present the company and its lead candidate drug, LIB-01, at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in February.
The interim report will be presented by CEO Elin Trampe and CFO Björn Petersson in a live broadcast from Direkt Studio today Wednesday February 18 at 12.00 CEST. The broadcast can be viewed on PRESENTATION or via a link at www.dicotpharma.com. The broadcast can be viewed afterwards via the same link.